LINE vs OGN · rev $5.34B vs P/E 3.4, rev $6.40B
Lineage, Inc. Common Stock (LINE) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Lineage, Inc. Common Stock (LINE) is a reit - industrial company listed on NASDAQ.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported LINE revenue for 2024-12-31 was $5.34B. Net income was -$751.0M. Revenue was down 0.0% from 2023-12-31 to 2024-12-31. LINE currently screens at market cap $10.41B.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
LINE currently screens at market cap $10.41B. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the LINE and OGN stock pages for the full models.
Not investment advice.